Medicenna Therapeutics Corp (TSE:MDNA) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Medicenna Therapeutics Corp announced that updated clinical data from its Phase 1/2 ABILITY-1 study will be presented at the 2024 Immunotherapy Bridge Conference. The study evaluates MDNA11, an innovative IL-2 super-agonist, in treating advanced solid tumors. This development underscores Medicenna’s commitment to advancing cancer immunotherapies.
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue